Skip to content

Stoke Therapeutics, Inc.

STOK· Nasdaqxbrl foundCIK 1623526
Last sale
Nov 12, 2026 · -5.57%
Market cap
$1.71B
65.41M shares
Filings
636
$11.26M
Q3 2026+404.5% FY25 yoy
-$73.64M
Q3 2026N/M FY25 yoy
-$77.32M
Q3 2026N/M FY25 yoy
-$185.03M
Q3 2026derivedN/M FY25 yoy
-$1.08
Q3 2026N/M FY25 yoy
$107.27M
Q3 2026−34.2% FY25 yoy
$1.71B
—
60.7×
4.9×
-12.60%
—

Twelve months to Sep 30, 2026 · derived

Financials

Revenue

$184.42MFY 2025
$184.42M0FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$184,420,000reported
FY 20242024-12-31$36,555,000reported
FY 20232023-12-31$8,780,000reported
FY 20222022-12-31$12,405,000reported

Stoke Therapeutics, Inc. · CIK 1623526 · Engraved from SEC EDGAR